Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $156.38, suggesting potential stock growth. The company is financially strong with over €1.1 billion in cash and investments, securing operations through late 2029. Leadership enhancements and reduced future payment obligations position Abivax well for commercialization and growth.
Abivax's recent FDA feedback and analyst outlook provide context for readers. For those tracking health-sector stocks, here is Pluang's market snapshot as of Sep 22, 2026 20:31 WIB: Among 101 priced US health stocks, 54 rose and 41 fell. Notable movers include HRTX at USD 0.28 with a 3.41% gain, CTXR at USD 0.59 up 2.91%, and AMGN at USD 404.00 rising 2.76%.
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
